BridgeBio Oncology Therapeutics (BBOT) Retained Earnings (2023 - 2026)

BridgeBio Oncology Therapeutics has reported Retained Earnings for 4 years, with the latest figure at -$981000.0 in Q1 2026.

• Quarterly Retained Earnings rose 84.05% year-over-year to -$981000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$981000.0 (up 84.05% YoY) and the FY2025 annual result came in at -$356.6 million, down 918.98% from the prior year.
• Retained Earnings advanced to -$981000.0 in Q1 2026 per BBOT's latest filing, from -$356.6 million in the prior quarter.
• Over five years, Retained Earnings peaked at $43.5 million in Q4 2024 and troughed at -$356.6 million in Q4 2025.
• A 4-year average of -$33.7 million and a median of -$3.3 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 177316.46% in 2024, then slumped 918.98% in 2025.
• Over 4 years, Retained Earnings stood at $24540.0 in 2023, then surged by 177316.46% to $43.5 million in 2024, then plunged by 918.98% to -$356.6 million in 2025, then soared by 99.72% to -$981000.0 in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$981000.0, -$356.6 million, and $36000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.